3,10-dihydroxy-2-naphthacene Carboxamide Or Derivative (e.g., Tetracycline, Etc.) Doai Patents (Class 514/152)
-
Publication number: 20100113400Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: May 28, 2009Publication date: May 6, 2010Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Mohamed Y. Ismail, Laura Honeyman, Todd Bowser, Beena Bhatia
-
Publication number: 20100113401Abstract: Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.Type: ApplicationFiled: October 29, 2009Publication date: May 6, 2010Applicant: Paratek Pharmaceuticals, Inc.Inventors: Sean Johnston, Tadeusz Warchol
-
Patent number: 7705168Abstract: Disclosed herein is a manufacturing process for the preparation of tigecycline suitable for intravenous infusion.Type: GrantFiled: June 16, 2006Date of Patent: April 27, 2010Assignee: Wyeth LLCInventors: Gurmukh Chanana, Dominic Ventura, Richard Saunders, Mahdi B. Fawzi
-
Publication number: 20100098744Abstract: Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective.Type: ApplicationFiled: October 14, 2009Publication date: April 22, 2010Applicant: Metronic, Inc.Inventors: William V. Ferris, Thomas C. Bischoff
-
Patent number: 7696186Abstract: The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: December 16, 2003Date of Patent: April 13, 2010Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Laura McIntyre, Beena Bhatia, Paul Hawkins, Laxma Reddy, Karen Stapleton, Tadeusz Warchol, Paul Sheahan
-
Patent number: 7696187Abstract: The present invention relates to 9-substituted tetracycline derivatives as well as compositions and use thereof.Type: GrantFiled: March 28, 2006Date of Patent: April 13, 2010Assignee: Trustees of Tufts CollegeInventors: Mark L. Nelson, Glen Rennie, Darrell J. Koza
-
Patent number: 7696188Abstract: 7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described.Type: GrantFiled: March 4, 2008Date of Patent: April 13, 2010Assignee: Trustees of Tufts CollegeInventors: Mark L. Nelson, Darrell J. Koza, Glen Rennie
-
Patent number: 7691831Abstract: A method for treatment for conditions in human beings associated with either or both reactive arthritis or bursitis comprising administering a combination of a member from each of the following groups of medications: (1) synthetic purine nucleoside analog antiviral drugs, (2) antibiotic drugs, and (3) imidazole drugs. Alternate embodiments of the invention include dual combinations of (A) a member of the synthetic purine nucleoside analog group of antiviral drugs and a member of the antibiotic group of drugs, (B) a member of the antibiotic group of drugs and a member of the imidazole family of drugs, and (C) a member of the synthetic purine nucleoside analog group of antiviral drugs and a member of the imidazole group of drugs.Type: GrantFiled: March 29, 2005Date of Patent: April 6, 2010Inventors: Ernest L. Bonner, Jr., Robert Hines
-
Publication number: 20100074940Abstract: The present invention is directed to linear, biodegradable polyesteramide (PEA) polymers synthesized with repeating units derived from aminophenol esters and diacids. These PEAs have a monomer repeat represented by as well as a variety of uses to coat, form or comprise medical devices, combination medical devices and pharmaceutical compositions, including sustained release formulations.Type: ApplicationFiled: September 22, 2009Publication date: March 25, 2010Inventors: Arthur Schwartz, Satish Pulapura, Sarita Nethula, Archana Rajaram, Arikha Moses
-
Publication number: 20100075929Abstract: A compound of formula (I):Type: ApplicationFiled: November 24, 2009Publication date: March 25, 2010Applicant: Paratek Pharmaceuticals, Inc.Inventors: Carmen García-Luzón, Juan Carlos Cuevas, Jose M. Fiandor, Araceli Mallo, Mark L. Nelson, Roger Frechette
-
Publication number: 20100057047Abstract: A nasal delivery device for and method of delivering substance to the middle meatus in a nasal cavity of a subject in the treatment of a condition, in particular an inflammatory or infectious condition, thereof, the delivery device comprising: a nosepiece unit (17) including a nosepiece (20) for fitting to a nostril of a subject and a nozzle (25) through which substance is in use delivered to the respective nasal cavity; and a delivery unit (29) for delivering substance through the nozzle of the nosepiece; wherein the delivery device is configured to provide for deposition of a significant fraction of the delivered dose on, around and in the vicinity of the middle meatus.Type: ApplicationFiled: February 14, 2007Publication date: March 4, 2010Applicant: OptiNose ASInventors: Per Gisle Djupesland, Colin David Sheldrake, Roderick Peter Hafner
-
Publication number: 20100048510Abstract: Methods for disrupting amyloid fibrils in a subject, comprising combining an effective amount of a ?-2 microglobulin fibril disrupting compound with a medium associated with the subject, are disclosed. The invention also relates to combining the ?-2 microglobulin fibril disrupting compound ex vivo with the blood during dialysis treatment of an animal. It also relates to methods for determining which compounds are effective at disrupting amyloid fibrils in a medium.Type: ApplicationFiled: December 14, 2007Publication date: February 25, 2010Inventors: David S. Eisenberg, Melinda Balbirnie
-
Publication number: 20100047256Abstract: The present invention relates to methods of diagnosing, prognosing, preventing or delaying onset of or treating rheumatoid arthritis, methods of distinguishing between different types or stages of rheumatoid arthritis, of identifying an individual at risk of developing rheumatoid arthritis, and of monitoring efficacy of a treatment regime in an individual being treated for rheumatoid arthritis, using a citrullinated enolase peptide to detect or capture antibodies associated with rheumatoid arthritis.Type: ApplicationFiled: January 25, 2007Publication date: February 25, 2010Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Karin Lundberg, Patrick Venables, Andrew Kinloch
-
Publication number: 20100040685Abstract: Disclosed herein are a collagen-based matrix for use as a restorative material and a method for the preparation thereof. An atelocollagen dispersion is spread at a predetermined thickness over a plate and freeze-dried to form a porous collagen membrane. An atelocollagen dispersion is separately spread over a plate and pressurized to form a dense collagen membrane. This is overlaid with the porous collagen membrane and immersed in an EDS solution in ethanol to crosslink the two membranes with each other. From the bilayer structure thus constructed, EDS is removed, followed by lyophilization and cutting into an appropriate size.Type: ApplicationFiled: April 15, 2009Publication date: February 18, 2010Applicant: DALIM TISSEN Inc.Inventors: Seong-Ki LEE, Si-Nae Park, Sang-Hee Bae
-
Publication number: 20100035847Abstract: The invention relates to genetically engineered cells, and to proteins and genes useful in the production of tetracycline compounds, to methods of producing tetracycline compounds, and to tetracyclines thereby produced. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway.Type: ApplicationFiled: August 6, 2009Publication date: February 11, 2010Inventors: Hrvoje Petkovic, Peter Raspor, Urska Lesnik
-
Publication number: 20100035845Abstract: The invention is directed to a frozen pharmaceutical formulation suitable for administration to a subject parenterally, comprising a therapeutically effective amount of tigecycline and an agent selected from the group consisting of lactose, dextrose, glucose, mannose, sucrose, ribose, xylose and a combination thereof, wherein the formulation in a pre-frozen state at about 22° C. or in an unfrozen state at about 22° C. has a pH in the range of from 4.0 to 5.5. Preferably, the formulation is suitable for storage at or below about ?20° C. over a period of at least about 2 months, preferably 6 months, more preferably 26 months. Alternatively, the formulation is suitable for storage at about 22° C. over a period of about 24 hours.Type: ApplicationFiled: August 5, 2009Publication date: February 11, 2010Applicant: WyethInventors: Christian Luther OFSLAGER, Nataliya BAZHINA, Mahdi Bakir FAWZI, Syed Muzafar SHAH, Gurmukh Das CHANANA
-
Publication number: 20100035846Abstract: An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9±0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9±0.2% hydroxypropoxylated.Type: ApplicationFiled: August 5, 2009Publication date: February 11, 2010Inventors: Mitchell Wortzman, R. Todd Plott, Steven B. Newhard, David Watt
-
Publication number: 20100034745Abstract: The subject invention concerns the reduction of protein aggregation in the neurons of a mammal through the use of a ketogenic treatment such as a ketogenic diet, a physical training regimen and/or administration of agents to increase fatty acid oxidation. Such ketogenic treatment can be useful in the reduction of certain aggregates including amyloid ? peptide, polyglutamine containing huntintin protein, polyglutamine containing androgen receptor, polyglutamine containing atrophin-1, polyglutamine containing ataxins, ?-synclein, prion protein, tau and superoxide dismutase 1 (SOD1).Type: ApplicationFiled: July 8, 2009Publication date: February 11, 2010Applicant: NEUERA PHARMACEUTICALS, INC.Inventor: Samuel T. Henderson
-
Publication number: 20100028396Abstract: The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold.Type: ApplicationFiled: July 30, 2009Publication date: February 4, 2010Inventors: Brian Roderick WARD, Keryn Dallas JOHNSON, Barnaby Charles Hough MAY
-
Publication number: 20100022483Abstract: The present invention pertains, at least in part, to methods of treating a microorganism-associated infection in a subject comprising administering to said subject an effective amount of a tetracycline compound.Type: ApplicationFiled: April 14, 2009Publication date: January 28, 2010Applicant: Paratek Pharmaceuticals, Inc.Inventors: Joel Berniac, Todd Bowser
-
Patent number: 7652002Abstract: A compound of formula (I):Type: GrantFiled: December 20, 2006Date of Patent: January 26, 2010Assignee: Paratek Pharmaceuticals, Inc.Inventors: Carmen García-Luzón, Juan Carlos Cuevas, Jose M. Fiandor, Araceli Mallo, Mark L. Nelson, Roger Frechette
-
Publication number: 20100004211Abstract: 7-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.Type: ApplicationFiled: January 21, 2009Publication date: January 7, 2010Inventors: Mark L. Nelson, Darrell J. Koza
-
Publication number: 20090325908Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: January 9, 2009Publication date: December 31, 2009Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Y. Ismail, Todd Bowser, Jimmy Dumornay, Glen Rennie, Gui Liu, Darrell J. Koza, Paul Sheahan, Karen Stapleton, Paul Hawkins, Beena Bhatia, Atul K. Verma, Laura Honeyman, Tadeusz Warchol, David Messersmith
-
Publication number: 20090324558Abstract: The present invention relates to administering a doxycycline compound into a diseased intervertebral disc.Type: ApplicationFiled: May 14, 2009Publication date: December 31, 2009Applicant: DePuy Spine, Inc.Inventors: Mohamed Attawia, Thomas M. DiMauro, Hassan Serhan, Sudhakar Kadiyala, David Urbahns, Gregory Collins, Laura J. Brown, Jeffrey C. Geesin
-
Publication number: 20090325909Abstract: The invention provides a new and effective treatment for human immunodeficiency diseases, particularly for HIV-infected individuals. The treatment utilizes tetracycline analogs, particularly minocycline, in amounts that are effective to prevent HIV replication both the central nervous system and in peripheral blood.Type: ApplicationFiled: September 27, 2004Publication date: December 31, 2009Applicant: The Johns Hopkins UniversityInventors: Mary C. Zink, Sheila A. Barber
-
Publication number: 20090306022Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: ApplicationFiled: June 9, 2009Publication date: December 10, 2009Applicants: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Mohamed Ismail, Todd Bowser, Beena Bhatia, David Messersmith, Laura McIntyre, Darrell Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul Verma, Tadeusz Warchol, Upul Bandarage
-
Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions
Publication number: 20090291925Abstract: Bioactive liquid formulations are formed of combinations of absorbable, segmented aliphatic polyurethane compositions and liquid polyether for use as vehicles for the controlled release of at least one active agent for the conventional and unconventional treatment of different forms of cancer and the management of at least one type of bacterial, fungal, and viral infection.Type: ApplicationFiled: May 22, 2009Publication date: November 26, 2009Inventor: Shalaby W. Shalaby -
Publication number: 20090281068Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.Type: ApplicationFiled: April 21, 2006Publication date: November 12, 2009Inventors: Michael Moller, Thomas Trimaille, Robert Gurny
-
Patent number: 7612053Abstract: 7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described.Type: GrantFiled: December 16, 2005Date of Patent: November 3, 2009Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Laura McIntyre
-
Patent number: 7612045Abstract: The present invention provides compounds and compositions useful for controlling bacterial biofilms as well as for controlling and/or preventing bacterial infections. The compounds of the invention are pentacyclic acid triterpenes. Methods for controlling biofilms and for controlling and/or preventing bacterial infections are also disclosed.Type: GrantFiled: September 14, 2005Date of Patent: November 3, 2009Assignee: Sequoia Sciences, Inc.Inventor: Gary R. Eldridge
-
Publication number: 20090258842Abstract: 7-phenyl-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described.Type: ApplicationFiled: April 17, 2009Publication date: October 15, 2009Applicant: Trustees of Tufts CollegeInventors: Mark L. Nelson, Glen Rennie, Darrell Koza
-
Publication number: 20090253660Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.Type: ApplicationFiled: March 5, 2009Publication date: October 8, 2009Applicant: Paratek Pharmaceuticals, Inc.Inventor: Sean Johnston
-
Patent number: 7595309Abstract: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: May 24, 2004Date of Patent: September 29, 2009Assignees: Trustees of Tufts College, Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Peter Viski, Beena Bhatia, David Messersmith, Mohamed Y. Ismail, Todd Bowser, Laura McIntyre, Darrell J. Koza, Glen Rennie, Paul Sheahan, Paul Hawkins, Atul K. Verma, Tadeusz Warchol, Upul Bandarage
-
Publication number: 20090232899Abstract: A nanocomposite delivery system uses chitosan as a mucoadhesive material encapsulated in a surface modified network of colloidal nanoporous nanoparticles, such as silica, or other colloid-forming materials, especially metal oxides. Drug delivery systems may be provided by binding a drug to the chitosan/silica nanocomposite, typically by adding a drug or other active agent during in-situ gellation of colloidal silica. When the active agent is, for example, amoxicillin or other antibiotic agent, the drug delivery system may be used in the treatment of stomach ulcers, for example.Type: ApplicationFiled: May 20, 2005Publication date: September 17, 2009Inventors: Allan E. David, Rulyun Zhang, Yoon Jeong Park, Arthur Jin-Ming Yang, Victor C. Yang
-
Publication number: 20090221533Abstract: The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestional operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.Type: ApplicationFiled: July 28, 2006Publication date: September 3, 2009Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Mark Puder, Marsha A. Moses
-
Publication number: 20090176747Abstract: The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders.Type: ApplicationFiled: September 29, 2008Publication date: July 9, 2009Applicant: National Institutes of HealthInventors: Yves Pommier, Laurent Thibaut, Christophe Marchand
-
Patent number: 7553827Abstract: The present invention relates to injecting a cycline compound into a diseased intervertebral disc.Type: GrantFiled: August 13, 2003Date of Patent: June 30, 2009Assignee: DePuy Spine, Inc.Inventors: Mohamed Attawia, Thomas M. DiMauro, Hassan Serhan, Sudhakar Kadiyala, David Urbahns, Scott Bruder, Laura J. Brown, Jeffrey C. Geesin
-
Patent number: 7553828Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.Type: GrantFiled: February 24, 2004Date of Patent: June 30, 2009Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Roger Frechette, Mohamed Y. Ismail, Laura Honeyman, Todd Bowser, Beena Bhatia
-
Publication number: 20090155326Abstract: The present invention is directed generally to a layered polymeric monofilament fiber drug delivery device, where each layer of the device can contain a different polymer, drug, additive, or any combination or mixture thereof. The layered nature of the current monofilament polymeric monofilament device provides the capability to modulate the release of one or more drugs and/or the mechanical properties of the fiber so that drug release and device failure can be separately tuned to provide for the tailored introduction of therapeutically effective drugs or agents to a target tissue. Moreover, the fiber may comprise more than one distinct segments along its length, each segment itself having different combinations and/or numbers of layers thereby providing even greater freedom in the design of the therapeutic delivery device. The invention is also directed to a method of manufacturing such a layered polymeric monofilament fiber drug delivery device, and methods of treatment using such devices.Type: ApplicationFiled: November 12, 2008Publication date: June 18, 2009Inventors: Brendan C. Mack, Mark E. Davis, Kenneth W. Wright
-
Patent number: 7544373Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.Type: GrantFiled: April 2, 2007Date of Patent: June 9, 2009Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
-
Patent number: 7541347Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.Type: GrantFiled: April 2, 2007Date of Patent: June 2, 2009Assignee: Medicis Pharmaceutical CoroprationInventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
-
Publication number: 20090137533Abstract: The present invention offers an eyelid treatment kit used for convenient combination therapy for improving overall eyelid hygiene while also providing for adjunctive eyelid therapy. The eyelid treatment kit comprises low dose doxycycline hyclate tablets, a non-irritating eyelid cleansing composition, an anti-bacterial eyelid preparation and at least one pair of moist heat goggles and/or one pair of moisture chamber goggles. The eyelid treatment kit further comprises instruction sheets containing dosage and administration information on the doxycycline hyclate coupled with information on improving eyelid hygiene. The various embodiments of the eyelid treatment kit of the invention facilitate treatment of dry eyes due to infected eyelids, and proper cleansing of the eyelids to prevent recurring infections.Type: ApplicationFiled: December 30, 2008Publication date: May 28, 2009Inventor: Nat G. Adkins, JR.
-
Publication number: 20090136568Abstract: A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Preferred anti static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate.Type: ApplicationFiled: October 28, 2005Publication date: May 28, 2009Applicant: Mayne Pharma International Pty LtdInventor: Stefan Lukas
-
Publication number: 20090124583Abstract: 7-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.Type: ApplicationFiled: May 30, 2008Publication date: May 14, 2009Applicant: Trustees of Tufts CollegeInventors: Mark L. Nelson, Darrell Koza
-
Publication number: 20090118240Abstract: A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.Type: ApplicationFiled: February 2, 2006Publication date: May 7, 2009Inventors: Ruihong Chen, Allan E. Rubenstein, Xiaodong Shen, Scott Stewart, Jin-Chen Yu
-
Publication number: 20090111776Abstract: In accordance with one aspect, the present invention provides a compound of general formula (I), its stereoisomers thereof and/or its pharmaceutically acceptable salts thereof, which have antibacterial activity; with methods of treating infectious diseases in warm blooded animals employing these new compounds. wherein R1 is selected from optionally substituted alkyl.Type: ApplicationFiled: September 8, 2008Publication date: April 30, 2009Applicants: Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc.Inventors: Mohamed Takhi, Natesan Selvakumar, Gavara Govinda Rajulu, Javed Iqbal, Sreenivas Kandepu
-
Publication number: 20090104121Abstract: Provided herein are methods and compositions for the in vitro formation of multi subunit biological platforms. The biological platforms may be used to screen chemical or biological compounds, in particular compounds that may disrupt or otherwise affect the formation of the multi subunit complexes, or disrupt already-formed in vitro assembled multi subunit complexes. Also provided herein are methods and compositions for the in vivo formation of multi-subunit biological complexes. The methods and compositions described herein may be used to develop animal models of diseases or disorders.Type: ApplicationFiled: September 29, 2008Publication date: April 23, 2009Applicant: Plaxgen, IncInventor: Shanmugavel Madasamy
-
Patent number: 7521437Abstract: 7-phenyl-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described.Type: GrantFiled: February 13, 2007Date of Patent: April 21, 2009Assignee: Trustees of Tufts CollegeInventors: Mark L. Nelson, Glen Rennie, Darrell J. Koza
-
Publication number: 20090098203Abstract: Mucositis is treated and/or prevented by administrating to a patient a formulation containing a tetracycline and at least one cationic polymer and/or mucoadhesive material. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal overgrowth due to reduction in the normal oral flora by the tetracycline. The formulation can be formed into liquid or solid dosage forms such as mouth rinse or tablet. Such compositions have the advantage of prolonged retention of the tetracycline in the mucosa of the oral cavity.Type: ApplicationFiled: May 16, 2008Publication date: April 16, 2009Inventor: James Ronald Lawter
-
Publication number: 20090069274Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.Type: ApplicationFiled: October 16, 2007Publication date: March 12, 2009Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant